![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ADGRF4 |
Gene summary for ADGRF4 |
![]() |
Gene information | Species | Human | Gene symbol | ADGRF4 | Gene ID | 221393 |
Gene name | adhesion G protein-coupled receptor F4 | |
Gene Alias | GPR115 | |
Cytomap | 6p12.3 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q8IZF3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
221393 | ADGRF4 | P31T-E | Human | Esophagus | ESCC | 6.19e-03 | 1.47e-01 | 0.1251 |
221393 | ADGRF4 | P37T-E | Human | Esophagus | ESCC | 2.67e-02 | 6.23e-02 | 0.1371 |
221393 | ADGRF4 | P44T-E | Human | Esophagus | ESCC | 6.06e-03 | 1.59e-01 | 0.1096 |
221393 | ADGRF4 | P47T-E | Human | Esophagus | ESCC | 8.35e-04 | 9.76e-02 | 0.1067 |
221393 | ADGRF4 | P49T-E | Human | Esophagus | ESCC | 2.63e-03 | 5.04e-01 | 0.1768 |
221393 | ADGRF4 | P61T-E | Human | Esophagus | ESCC | 3.13e-02 | 1.86e-01 | 0.099 |
221393 | ADGRF4 | P62T-E | Human | Esophagus | ESCC | 2.51e-02 | 1.10e-01 | 0.1302 |
221393 | ADGRF4 | P65T-E | Human | Esophagus | ESCC | 1.48e-02 | 1.16e-01 | 0.0978 |
221393 | ADGRF4 | P75T-E | Human | Esophagus | ESCC | 2.55e-04 | 1.43e-01 | 0.1125 |
221393 | ADGRF4 | P80T-E | Human | Esophagus | ESCC | 5.61e-27 | 1.00e+00 | 0.155 |
221393 | ADGRF4 | P130T-E | Human | Esophagus | ESCC | 8.86e-18 | 4.12e-01 | 0.1676 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ADGRF4 | SNV | Missense_Mutation | novel | c.589N>A | p.Ala197Thr | p.A197T | Q8IZF3 | protein_coding | tolerated(0.18) | benign(0) | TCGA-95-7567-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
ADGRF4 | SNV | Missense_Mutation | c.1429A>C | p.Thr477Pro | p.T477P | Q8IZF3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-97-7937-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ADGRF4 | SNV | Missense_Mutation | novel | c.230N>A | p.Thr77Lys | p.T77K | Q8IZF3 | protein_coding | tolerated(0.25) | benign(0.035) | TCGA-L9-A444-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ADGRF4 | SNV | Missense_Mutation | novel | c.1609N>T | p.Thr537Ser | p.T537S | Q8IZF3 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-L9-A444-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ADGRF4 | SNV | Missense_Mutation | novel | c.217N>C | p.Glu73Gln | p.E73Q | Q8IZF3 | protein_coding | tolerated(0.06) | possibly_damaging(0.858) | TCGA-21-1082-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ADGRF4 | SNV | Missense_Mutation | novel | c.1880N>T | p.Glu627Val | p.E627V | Q8IZF3 | protein_coding | deleterious(0.01) | possibly_damaging(0.588) | TCGA-22-4594-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ADGRF4 | SNV | Missense_Mutation | novel | c.553A>G | p.Ser185Gly | p.S185G | Q8IZF3 | protein_coding | deleterious(0.03) | benign(0.345) | TCGA-34-2605-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | PD |
ADGRF4 | SNV | Missense_Mutation | c.741N>G | p.Ile247Met | p.I247M | Q8IZF3 | protein_coding | deleterious(0.02) | benign(0.174) | TCGA-37-3783-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ADGRF4 | SNV | Missense_Mutation | c.1883N>C | p.Gly628Ala | p.G628A | Q8IZF3 | protein_coding | deleterious(0.02) | benign(0.307) | TCGA-43-7656-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ADGRF4 | SNV | Missense_Mutation | rs774783551 | c.276N>A | p.Ser92Arg | p.S92R | Q8IZF3 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-63-6202-01 | Lung | lung squamous cell carcinoma | Male | Unknown | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |